(Q32045067)

5 July 2017

Efficacy and safety of desensitization to allopurinol following cutaneous reactions (English)

1 reference

5 July 2017

1 reference

1 reference

Fam AG

1

1 reference

5 July 2017

Dunne SM

series ordinal

2

1 reference

5 July 2017

Iazzetta J

series ordinal

3

1 reference

5 July 2017

Paton TW

series ordinal

4

1 reference

5 July 2017

1 January 2001

1 reference

5 July 2017

Arthritis & Rheumatology

1 reference

5 July 2017

44

1 reference

5 July 2017

231-238

1 reference

5 July 2017

1

1 reference

Acute adverse reactions attributed to allopurinol in hospitalised patients

5 July 2017

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200101%2944%3A1%3C231%3A%3AAID-ANR30%3E3.0.CO%3B2-7

Sulphasalazine in rheumatoid arthritis: desensitising the patient with a skin rash

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200101%2944%3A1%3C231%3A%3AAID-ANR30%3E3.0.CO%3B2-7

Trimethoprim/sulfamethoxazole incremental dose regimen in human immunodeficiency virus-infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200101%2944%3A1%3C231%3A%3AAID-ANR30%3E3.0.CO%3B2-7

Desensitisation in a patient with chronic renal disease and severe allergy to allopurinol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200101%2944%3A1%3C231%3A%3AAID-ANR30%3E3.0.CO%3B2-7

Desensitisation to allopurinol: a cautionary tale

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200101%2944%3A1%3C231%3A%3AAID-ANR30%3E3.0.CO%3B2-7

Desensitisation to allopurinol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200101%2944%3A1%3C231%3A%3AAID-ANR30%3E3.0.CO%3B2-7

Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200101%2944%3A1%3C231%3A%3AAID-ANR30%3E3.0.CO%3B2-7

The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200101%2944%3A1%3C231%3A%3AAID-ANR30%3E3.0.CO%3B2-7

Allopurinol hypersensitivity syndrome: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200101%2944%3A1%3C231%3A%3AAID-ANR30%3E3.0.CO%3B2-7

Strategies and controversies in the treatment of gout and hyperuricaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200101%2944%3A1%3C231%3A%3AAID-ANR30%3E3.0.CO%3B2-7

21 January 2018

The management of gout

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200101%2944%3A1%3C231%3A%3AAID-ANR30%3E3.0.CO%3B2-7

Tumor lysis syndrome: pathogenesis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200101%2944%3A1%3C231%3A%3AAID-ANR30%3E3.0.CO%3B2-7

Allergic Reaction to Allopurinol with Cross-Reactivity to Oxypurinol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200101%2944%3A1%3C231%3A%3AAID-ANR30%3E3.0.CO%3B2-7

Advances in the management of malignancy-associated hyperuricaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200101%2944%3A1%3C231%3A%3AAID-ANR30%3E3.0.CO%3B2-7

Generation of cDNA probes directed by amino acid sequence: cloning of urate oxidase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200101%2944%3A1%3C231%3A%3AAID-ANR30%3E3.0.CO%3B2-7

Excellent uricosuric efficacy of benzbromarone in cyclosporin-A-treated renal transplant patients: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200101%2944%3A1%3C231%3A%3AAID-ANR30%3E3.0.CO%3B2-7

Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200101%2944%3A1%3C231%3A%3AAID-ANR30%3E3.0.CO%3B2-7

Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200101%2944%3A1%3C231%3A%3AAID-ANR30%3E3.0.CO%3B2-7

Severe adverse cutaneous reactions to drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200101%2944%3A1%3C231%3A%3AAID-ANR30%3E3.0.CO%3B2-7

10.1002/1529-0131(200101)44:1<231::AID-ANR30>3.0.CO;2-7

21 January 2018

Identifiers

DOI

1 reference

release_ujqmvjgysbhqfliftzt2egtjmq

5 July 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ujqmvjgysbhqfliftzt2egtjmq

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference